Liver Cancer
ADI-PEG 20 for Advanced Hepatocellular Carcinoma (20120106)
POLARIS2009-001: A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Investigator: William P. Harris, MD; Conditions: Liver Cancer; Status: Recruiting; Study ID: NCT01287585
A Multicenter, Randomized, Double-blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) versus Placebo and BSC as Second-line Treatment in Patients With Hepatocellular Carcinoma Following First-line Therapy With Sorafenib
Investigator: William Harris; Conditions: Gastrointestinal Cancer, Liver Cancer; Status: Recruiting; Study ID: NCT01140347
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Emboliztion (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study
Investigator: Edward Lin, MD; Conditions: Liver Cancer; Status: Closed; Study ID: NCT00908752
Join Us On